



## DEVELOPMENT, SYNTHESIS AND ASSESSMENT OF ANTI-INFLAMMATORY ACTIVITY OF CHROMONES DERIVATIVES

Vishal Gupta<sup>1\*</sup>, Gautam Girendra Kumar<sup>2</sup> and S K Yadav<sup>3</sup>

<sup>1</sup>Research Scholar, Institute of Pharmaceutical science and research center, Bhagwant University, Ajmer, Rajasthan, India.

<sup>2</sup>Supervisor, Institute of Pharmaceutical science and research center, Bhagwant University, Ajmer, Rajasthan, India.

<sup>3</sup>Supervisor, Technocrat Institute of Technology –Pharmacy, Anand Nagar Bhopal (MP)

\*Corresponding Author's E mail: [vishalpharmacy@rediffmail.com](mailto:vishalpharmacy@rediffmail.com)

Received 20 Dec. 2017; Revised 25 Dec. 2017; Accepted 10 Jan. 2018, Available online 20 Jan. 2018

### ABSTRACT

SnCl<sub>4</sub> catalyzed Claisen rearrangement of allyl aryl ethers followed by cyclization gives oxygen hetrocycles. By utilizing SnCl<sub>4</sub> as lewis acid the rearrangement reaction is affected under mild condition. The antiinflammatory activity of the synthesized compounds was determined by rat paw edema method. Some of the compounds were found to be potent.

**Keywords:** NSAID, Synthesized compounds, Antiinflammatory activity

### INTRODUCTION

Non-steroidal antiinflammatory drugs are widely used to treat pain, fever and inflammatory condition including osteoarthritis. Several research studies exhibits the antiinflammatory properties of chromones. <sup>1-3</sup> Chromones are also reported as antimicrobial<sup>4,5</sup>, anticancer<sup>6</sup>, antiallergic<sup>7</sup> and coronary vasodilator<sup>8</sup>. Claisen rearrangement is generally affected by prolong heating of an aryl allyl ether or by heating in vacuum at high temperature. Lewis acids are known to cause the Claisen rearrangement under mild conditions. The use of SnCl<sub>4</sub> as lewis acid act as a catalyst for Claisen rearrangement is not reported. We propose the SnCl<sub>4</sub> catalysed Claisen rearrangement of 7-allyloxy chromones to afford 7 hydroxy 6/8 allylchromones and 2'-methyl-2', 3'-dihydrofuronochromone.

7- hydroxyl chromones(2a-d) and 7-allyloxychromones(3a-d) were synthesized as per the reported methods<sup>9,10</sup>. 7-hydroxy-6/8-allylchromone (4a-d) and 2'-methyl-2',3'-dihydrofurano chromones (5a-d) were synthesized by the treatment of 7-allyloxychromones(3a-d) with SnCl<sub>4</sub> in dry THF (Scheme-1).



**Table-1 Characterization and antiinflammatory activity of synthesized compounds**

Compounds	M.P(°C)	Yield (%)	Paw Volume (% protection)
Control			2.25± 0.08
Ibuprofen			0.89± 0.13(60)
4a	134	34	1.80± 0.19(20)
4b	147	36	1.73± 0.14(23)
4c	132	57	0.77± 0.18(66)
4d	176	74	1.08± 0.02(52)
5a	145	45	1.40± 0.01(38)
5b	139	51	1.64± 0.11(27)
5c	152	59	1.10± 0.13(54)
5d	182	45	1.54± 0.08(42)

The melting points were determined in open capillary tubes and are uncorrected. Elemental analysis was determined using Carlo Erba model 1108. IR Spectras were recorded on Perkin-Elmer 881 spectrophotometer in KBr( $\text{cm}^{-1}$ ) and  $^1\text{H}$  NMR spectra on a Brukers advanced DXP 200 spectrophotometer using TMS as internal reference.

#### Synthesis of 7- Hydroxyl chromones (2a-d) and 7-allyloxchromones (3a-d)

10 mmols of 1(a-d) and acetic anhydride were refluxed with 5% hydrochloric acid, methanol and sodium acetate at 180°C for 6h. The solution was filtered and the products (2a-d) were recovered. 10mmols of 2(a-d) and 20ml of propylene bromide were refluxed with acetone and potassium carbonate for 5h to obtain compounds 3(a-d).

Synthesis of 7-hydroxy-6/8-allylchromone (4a-d) and 2'-methyl-2', 3'-dihydrofurano chromones (5a-d): 10 mmols of 3(a-d) and SnCl<sub>4</sub> in dry THF(10ml) were stirred for 14 h under N<sub>2</sub> atmosphere at 0-5°C. The solution was filtered and solvent is removed under reduced pressure. The resulting mixture was chromatographed over silica gel. Elution with benzene-ethyl acetate (1:1, v/v) mixture gave two products 4 and 5. These compounds were crystallized from benzene. The compounds were subjected for NMR studies. 4a  $\delta$  1.95 (s, CH<sub>3</sub>-3), 2.35(s, CH<sub>3</sub>-2), 7.65(ar, H-5, J=10H-2), 3.52(m, H-1'), 5.05(dd, H-3', J=10, 1H-2), 9.95(dd, H-3', J=16, 1H-2), 5.90(m-H-2'), 10.20(s, 7-OH). 4b  $\delta$  1.96 (s, CH<sub>3</sub>-3), 2.38(s, CH<sub>3</sub>-2), 7.62(s, H-5), 3.59(m, H-1'), 5.91(m-H-2), 5.10(dd, H-3', J=10, 1H-2), 4.99(dd, H-3', J=16, 1H-2). 4c.  $\delta$  1.97 (s, CH<sub>3</sub>-3), 2.39(s, CH<sub>3</sub>-2), 7.64(s, H-5), 3.49(m, H-1'), 5.90(m-H-1'), 5.12(dd, H-3', J=10, 1H-2), 4.99(dd, H-3', J=16, 1H-2). 4d  $\delta$  2.10 (s, CH<sub>3</sub>-3), 2.46(s, CH<sub>3</sub>-2), 7.80(s, H-5), 2.30(s-CH<sub>3</sub>-1) 3.50(m, H-1'), 6.08(m-H-2), 5.30(dd, H-3', J=10, 1H-2), 5.09(dd, H-3', J=16, 1H-2). 5a.  $\delta$  1.50 (d, CH<sub>3</sub>-2', J=6H-2), 2.05(s, CH<sub>3</sub>-3), 2.45(s, CH<sub>3</sub>-2), 2.90(dd, H-3', J=12, 8H-2), 3.42(dd, H-3', J=16, 6H-2), 5.10(m, H-2'), 8.20(d, H-8, J=10H-2), 6.75(d, H-9, J=10 H-2). 5b  $\delta$  1.62(d-CH<sub>3</sub>-2', J=6H-2), 2.05 (s, CH<sub>3</sub>-3), 2.42(s, CH<sub>3</sub>-2), 3.02(dd, H-3', J=12, 8H-2), 3.56(dd, H-3', J-12, 6H-2), 5.25(m, H-2'), 8.12(s-H-5). 5c  $\delta$  1.62 (d, CH<sub>3</sub>-2', J=6H-2), 2.07(s, CH<sub>3</sub>-3), 2.41(s, CH<sub>3</sub>-2), 5.18(m, H-2'), 3.00(dd, H-3', J=12, 8H-2), 3.56(dd, H-3', J=12, 6H-2), 8.06(s, H-5). 5d  $\delta$  1.61(d, CH<sub>3</sub>-2', J=6H-2), 2.06 (s, CH<sub>3</sub>-3), 2.44(s, CH<sub>3</sub>-2), 2.30(s, CH<sub>3</sub>-8), 3.02(dd, H-3', J=12, 8H-2), 3.52(dd, H-3', J-12, 6H-2), 5.20(m, H-2'), 8.20(s, H-8).

### Acknowledgment

The authors are thankful to Principal and Chairman of Millennium College of Pharmacy, Bhopal for providing laboratory facilities and Central Drug Research Institute (CDRI), Lucknow for spectral analysis of the compounds.

### References

1. Inaba T, Tanaka K, Takeno R, Nagaki H, Yoshida C and Takano S. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem. Pharm. Bull (Tokyo). 2000; 48: 131-139.
2. Volovenko YM, Litenko VA, Babichev FS and Dashkovgkaya EV. Chemistry of Hetrocyclic comp. 1982; 18: 796.
3. Shokel TV, Khilya VP, Turov AV. Chemistry of Hetrocyclic comp. 2005; 41, 354.
4. Mazzei M, Scottotattori E, Dondero R, Ibrahim M and Farmco IL. 1999; 54: 452.
5. Garparova R, Lacova M, El-shaer HM, Odlerova Z, Farmco IL. 1997; 52:251.

6. Donnelly D and Geophegan R. *J.Med.Chem.* 1965; 8; 872.
7. Nohara A, Kuriki H, Saijo T, Sugihara H, Kanno M and Sannopp Y. *Med.Chem.*, 1977; 20: 141.
8. Bariana DS. *J.Med.Chem.*, 1969; 12: 927-928.
9. Kostenecki SV, Liold L, *Ber.* 1901; 34: 2948.
10. Rodighiero P, Pastorini G, Chrlin A, Manzini P and Guiotto A. *J. Heterocyclic Chem.*, 1988; 25: 527.
11. Winter CA, Risley EA and Nuss GN. *Proc.sec. Exp. Biol.*, 1962; 111: 544.